Portal Hypertension Pipeline Analysis Report 2025

Portal hypertension is a condition characterized by increased blood pressure within the portal venous system, commonly caused by cirrhosis, which accounts for 80%-90% of cases. According to the portal hypertension pipeline analysis by the publisher, the condition is driving focused research and development in novel therapeutics. The drug pipeline includes vasodilators, beta-blockers, and innovative agents targeting portal pressure reduction. With growing awareness, improved diagnostics, and advancements in pharmacological interventions, the pipeline is expected to witness significant growth in the coming years. The increasing prevalence of liver diseases is further fueling the demand for effective portal hypertension therapeutics.

Report Coverage

The Portal Hypertension Pipeline Analysis Report by the publisher gives comprehensive insights into portal hypertension therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for portal hypertension. The portal hypertension report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The portal hypertension pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with portal hypertension treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to portal hypertension.

Portal Hypertension Pipeline Outlook

Portal hypertension is a condition where there is increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. It occurs when there is obstruction or resistance to blood flow through the liver, often due to liver cirrhosis, leading to the development of collateral veins and complications such as varices and ascites.

Portal hypertension treatment includes the transjugular intrahepatic portosystemic shunt (TIPS) procedure, which diverts blood flow within the liver to decrease pressure in the portal vein and manage associated risks. In the drug pipeline, current approaches aim to control portal pressure using non-selective beta-blockers while also exploring minimally invasive interventions like TIPS to reduce the risk of serious outcomes.

Portal Hypertension Epidemiology

The drug pipeline for portal hypertension is evolving to address its growing clinical burden. According to a 2024 review, cirrhosis, the primary cause, accounted for 2.4% of global deaths in 2019. The age-standardised global prevalence reached 1.4%, highlighting a significant need for effective treatments. Ongoing research and development efforts focus on novel therapeutic targets to prevent hepatic decompensation and reduce mortality associated with this high-risk condition.

Portal Hypertension - Pipeline Therapeutic Assessment

This section of the report covers the analysis of portal hypertension drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Peptides
• RNA-based Therapies
• Gene Therapies
• Others

By Route of Administration

• Oral
• Parenteral
• Others

Portal Hypertension Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, in the portal hypertension clinical trials, phase II holds the largest share with 40%, reflecting strong innovation and early efficacy signals. Phase III follows at 34.29%, showing promising advancements toward regulatory approval. Phase IV contributes 22.86%, highlighting post-marketing validation, whereas early phase I represents 2.86%. These developments positively impact market growth, ensuring a robust future for treatment options.

Portal Hypertension Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the portal hypertension pipeline analysis include small molecules, biologics, peptides, RNA-based therapies, gene therapies, and others. The portal hypertension report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for portal hypertension.

Carbohydrate-based galectin inhibitors are gaining traction as a novel drug class in the portal hypertension pipeline. For instance, Belapectin, developed by Galectin Therapeutics, is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that targets the galectin-3 protein involved in fibrosis and inflammation. In the NAVIGATE trial, Belapectin showed a significant 68.1% reduction in new varices among U.S. patients with cirrhosis and portal hypertension, demonstrating promising therapeutic potential.

Portal Hypertension Clinical Trials - Key Players

The report for the portal hypertension pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed portal hypertension therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in portal hypertension clinical trials:

• Galectin Therapeutics Inc.
• Onyx Therapeutics, Inc.
• Novartis Pharmaceuticals
• Cumberland Pharmaceuticals
• Conatus Pharmaceuticals Inc.
• Boryung Pharmaceutical Co., Ltd.
• AstraZeneca
• Meridian Bioscience, Inc.
• Gilead Sciences
• Theravance Biopharma

Portal Hypertension - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for portal hypertension. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of portal hypertension drug candidates.

Drug: Zinc Acexamate

Zinc Acexamate is being evaluated in a Phase III trial sponsored by Hospital Universitari Vall d'Hebron Research Institute. This randomized, double-blind study is enrolling 300 patients to assess whether zinc supplementation improves prognosis in compensated advanced chronic liver disease. Zinc Acexamate is believed to enhance liver function, stabilize zinc homeostasis, reduce inflammation, and protect hepatocytes, potentially delaying decompensation and portal hypertension complications.

Alverine

Alverine, supported by Shanghai Changzheng Hospital, is currently undergoing a Phase II/III clinical trial to evaluate its safety and efficacy in treating cirrhotic portal hypertension. This study is examining Compound Alverine Citrate Capsules, combining 60 mg Alverine Citrate and 300 mg Simethicone. The drug is known for relaxing gut muscles and interacting with 5-HT receptors.

Key Questions Answered in the Portal Hypertension Pipeline Insight Report

• Which companies/institutions are leading the portal hypertension drug development?
• What is the efficacy and safety profile of portal hypertension pipeline drugs?
• Which company is leading the portal hypertension pipeline development activities?
• What is the current portal hypertension commercial assessment?
• What are the opportunities and challenges present in the portal hypertension pipeline landscape?
• What is the efficacy and safety profile of portal hypertension pipeline drugs?
• Which company is conducting major trials for portal hypertension drugs?
• Which companies/institutions are involved in portal hypertension collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in portal hypertension?

Reasons To Buy This Report

The Portal Hypertension Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for portal hypertension. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into portal hypertension collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.